SPHK1 and atherosclerosis: SphK1 deficiency abrogated cellular MCP-1 production when microvascular endothelial cells from Sphk1-deficient mice were treated with a protease-activated receptor 1-activating peptide [173], suggesting that SPHK1 inhibition is a novel therapeutic approach for atherosclerosis.